About Actelion
Actelion is a company based in Allschwil (Switzerland) founded in 1997 was acquired by Johnson & Johnson in January 2017. Actelion has raised $46 million across 2 funding rounds from investors including Johnson & Johnson, 3i Group and Atlas Venture. Actelion has completed 3 acquisitions, including Axovan, Ceptaris Therapeutics and CoTherix. Actelion operates in a competitive market with competitors including Aerovate Therapeutics, Centessa Pharmaceuticals, Vivus, Biosion and Tenax Therapeutics, among others.
- Headquarter Allschwil, Switzerland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Actelion Pharmaceuticals India Private Limited
- Date of Incorporation 08 Feb, 2008
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$46 M (USD)
in 2 rounds
-
Latest Funding Round
$34 M (USD), Series B
Mar 01, 1999
-
Investors
Johnson & Johnson
& 5 more
-
Employee Count
Not available
-
Investments & Acquisitions
Axovan
& 2 more
-
Acquired by
Johnson & Johnson
(Jan 26, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Actelion
Unlock access to complete
Unlock access to complete
Software Development Team
294 people
Leadership Team
141 people
Senior Team
50 people
Finance and Accounting
45 people
Data Analysis and Operations Team
41 people
Product Management Team
26 people
Legal and Compliance
26 people
Human Resources and Administration
26 people
Unlock access to complete
Funding Insights of Actelion
Actelion has successfully raised a total of $46M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in March 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Actelion
Actelion has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, 3i Group and Atlas Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital is invested in life science innovations for healthcare transformation.
|
Locked | Locked | Locked | |
|
Private equity firm focused on mid-market businesses
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked |
Investor details for Actelion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Actelion
Actelion has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Axovan, Ceptaris Therapeutics and CoTherix.
Investment portfolio details for Actelion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Mechlorethamine gel for mycosis fungoides is developed by Ceptaris Therapeutics.
|
Locked | Locked | 2002 | Locked | |
|
Drug development company specializing in G Protein-Coupled Receptors (GPCRs) targeting therapeutics
|
Locked | Locked | 2000 | Locked | |
|
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Actelion
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Actelion
Detailed financials for Actelion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Actelion Comparisons
Peer comparison for Actelion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Actelion
Actelion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aerovate Therapeutics, Centessa Pharmaceuticals, Vivus, Biosion and Tenax Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic solutions for pulmonary arterial hypertension are developed.
|
|
| Locked | Locked | Locked |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for obesity and sexual health
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics to address cardiovascular and pulmonary diseases
|
Detailed competitors of Actelion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Actelion
Complete news archive for Actelion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actelion
Actelion was founded in 1997 and raised its 1st funding round 1 year after it was founded.
Actelion is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.
Actelion is a funded company, having raised a total of $46M across 2 funding rounds to date.
Actelion specializes in small molecule therapeutics for orphan diseases. Actelion scientists were among the first to work in the field of endothelian receptor antagonists. Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries. Actelion currently has 10 compounds in its pipeline including 3 in late-stage development and 4 medicines on the market for orphan diseases: Tracleer (bosentan), a dual endothelin receptor antagonist which was the first oral treatment approved for pulmonary arterial hypertension; Zavesca (miglustat), currently the only approved oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Ventavis (iloprost), indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms; Veletri (epoprostenol for injection), approved for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Actelion's top competitors include Aerovate Therapeutics, Vivus and Centessa Pharmaceuticals.
Actelion has made 3 acquisitions, including Axovan, Ceptaris Therapeutics, and CoTherix.
Actelion has 6 investors. Key investors include Johnson & Johnson, 3i Group, Atlas Venture, TVM Capital Life Science, and NeoMed.